Aroa Biosurgery’s Myriad product family was a star performer of the company’s first profit since listing in 2020 and is ... Read More The post Myriad soft-tissue reconstruction products position Aroa ...

Myriad Genetics (MYGN), a leading developer of molecular diagnostic and therapeutic products, is predictably on track to expand its pipeline and broaden its markets in the U.S. and overseas. It is ...

Myriad also has a few promising products in its pipeline. One product, known as myRisk Hereditary Cancer, is expected to revolutionize hereditary cancer testing. myRisk is designed to solve the ...

The three products, Myriad™, Endoform® Natural and Endoform® Antimicrobial, have been approved under the ‘Medical Device Rules 2017’ by the national regulatory authority of India, the ...

Aroa Biosurgery Ltd (AU:ARX) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top StocksMake ...

Myriad then appealed to the U.S. Court of Appeals for the Federal Circuit, which reviews patent appeals from across the country. We filed amicus briefs , urging it to apply the Supreme Court's case ...

Myriad soft-tissue reconstruction products position Aroa for strong growth. Aroa Biosurgery’s Myriad product family was a star performer of the company’s first profit since listing in 2020 and ...